Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HuMax-IL8 · 1 trial · 1 indication
The primary endpoint of this study is the proportion of patients who experience DLTs. The MTD (Maximum Tolerated Dose) will be determined based on the dose escalation cohorts. The evaluation period for DLTs will be 28 days following the first dose of HuMax-IL8
| Arm | Type | Description |
|---|---|---|
| HuMax-IL8 | EXPERIMENTAL | HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle |
| Name | Type | Description |
|---|---|---|
| HuMax-IL8 | DRUG | HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle |
Inclusion Criteria: * Subjects must have metastatic or unresectable locally advanced malignant solid tumor. * Patients may have measurable or non-measurable but evaluable disease. * Patients with surgically resected metastatic disease at high risk of relapse are also eligible. * Patients must have ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
HuMax-IL8 is an investigational drug being studied for the treatment of solid tumors. It is currently in Phase 1 clinical development for this indication. The drug is being evaluated in patients with advanced malignant solid tumors.
HuMax-IL8 targets interleukin-8 (IL-8), a cytokine involved in tumor progression and inflammation. By targeting IL-8, the drug aims to interfere with the tumor microenvironment and potentially inhibit tumor growth. This mechanism is being explored in the context of solid tumor oncology.
HuMax-IL8 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research on this drug for the treatment of solid tumors.
HuMax-IL8 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical evaluation for solid tumors.
HuMax-IL8 has one completed clinical trial registered under NCT02536469, titled "HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors." This Phase 1 study enrolled 15 participants in the United States and was an uncontrolled, non-randomized trial.